Clinical Study
Immunosuppression Adversely Affects TST but Not IGRAs in Patients with Psoriasis or Inflammatory Musculoskeletal Diseases
Table 4
The univariate analysis of the TB risk factors with a positive outcome of the B-TbIFNg test.
| | Variable | All patients
| B-TbINFγ
| Odds ratio | Significance | | Positive (21.1) | (95% CI) | < |
| | Age, mean (test neg. mean) | 57.5 | 58.7 (58.8) | 1.0 (0.96–1.04) | 1 | | Sex, female, (%) | 65 (59.6) | 7 (46.7) | 0.6 (0.2–1.8) | 0.4 | | BCG vaccination, (%) | 46 (42.2) | 4 (26.7) | 0.4 (0.1–1.5) | 0.2 |
| | Born in TB-endemic country, (%) | 12 (11.0) | 3 (20.0) | 2.6 (0.5–12.2) | 0.3 | | Contact with TB, (%) | 15 (13.8) | 4 (26.7) | 3.0 (0.7–12.6) | 0.2 | | Previous TB-history, (%) | 12 (11.0) | 4 (26.7) | 3.7 (0.9–16.1) | 0.08 | | Any risk factor for LTBI, (%) | 33 (30.3) | 9 (60.0) | 5.0 (1.5–16.6) | 0.009 |
| | Positive chest X-ray, (%) | 8 (7.3) | 1 (7.1) | 0.9 (0.1–9.0) | 0.9 |
| | Group 1, (%) | 21 (19.3) | 2 (10.5) | 0.4 (0.07–1.7) | 0.2 | | Group 2, (%) | 71 (65.1) | 11 (24.4) | 1.3 (0.7–2.5) | 0.4 | | Group 3, (%) | 17 (15.6) | 2 (28.6) | 1.2 (0.6–2.1) | 0.6 |
| | Corticosteroids, (%) | 38 (34.9) | 3 (20.0) | 0.5 (0.1–2.1) | 0.4 | | Cytostatic treatment, (%) | 48 (44.0) | 6 (40.0) | 1.0 (0.3–3.3) | 1.0 | | Biological treatment, (%) | 6 (5.5) | 0 (0) | — | 1.0 |
|
|
